Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study.

Hill DA, Prossnitz ER, Royce M, Nibbe A.

PLoS One. 2019 Oct 24;14(10):e0224064. doi: 10.1371/journal.pone.0224064. eCollection 2019.

2.

Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics.

Blair CK, Wiggins CL, Nibbe AM, Storlie CB, Prossnitz ER, Royce M, Lomo LC, Hill DA.

NPJ Breast Cancer. 2019 Oct 2;5:33. doi: 10.1038/s41523-019-0128-4. eCollection 2019.

3.

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK.

JAMA Oncol. 2019 Jan 1;5(1):45-50. doi: 10.1001/jamaoncol.2018.3691.

4.

Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.

O'Shaughnessy J, Thaddeus Beck J, Royce M.

Cancer Treat Rev. 2018 Sep;69:204-214. doi: 10.1016/j.ctrv.2018.07.013. Epub 2018 Jul 23. Review.

5.

Breast cancer survival, survival disparities, and guideline-based treatment.

Hill DA, Friend S, Lomo L, Wiggins C, Barry M, Prossnitz E, Royce M.

Breast Cancer Res Treat. 2018 Jul;170(2):405-414. doi: 10.1007/s10549-018-4761-7. Epub 2018 Mar 22.

6.

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.

Royce M, Bachelot T, Villanueva C, Özgüroglu M, Azevedo SJ, Cruz FM, Debled M, Hegg R, Toyama T, Falkson C, Jeong J, Srimuninnimit V, Gradishar WJ, Arce C, Ridolfi A, Lin C, Cardoso F.

JAMA Oncol. 2018 Jul 1;4(7):977-984. doi: 10.1001/jamaoncol.2018.0060.

7.

Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.

Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.

J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.

8.

Estrogen receptor quantitative measures and breast cancer survival.

Hill DA, Barry M, Wiggins C, Nibbe A, Royce M, Prossnitz E, Lomo L.

Breast Cancer Res Treat. 2017 Dec;166(3):855-864. doi: 10.1007/s10549-017-4439-6. Epub 2017 Aug 19.

9.

The rs4646 and rs12592697 Polymorphisms in CYP19A1 Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds.

Armamento-Villareal R, Shah VO, Aguirre LE, Meisner AL, Qualls C, Royce ME.

Front Genet. 2016 Dec 2;7:211. eCollection 2016.

10.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

11.

Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.

Flores KG, Steffen LE, McLouth CJ, Vicuña BE, Gammon A, Kohlmann W, Vigil L, Dayao ZR, Royce ME, Kinney AY.

J Genet Couns. 2017 Jun;26(3):480-490. doi: 10.1007/s10897-016-0001-7. Epub 2016 Aug 6.

12.

New Agents for the Management of Advanced HER2-Positive Breast Cancer.

Royce M, Herold K.

J Adv Pract Oncol. 2016 Apr;7(3):295-298. Epub 2016 Apr 1. Review. No abstract available.

13.

The Changing Landscape of Breast Cancer: How Biology Drives Therapy.

Friend S, Royce M.

Medicines (Basel). 2016 Jan 21;3(1). pii: E2. doi: 10.3390/medicines3010002. Review.

14.

Everolimus in the Treatment of Metastatic Breast Cancer.

Royce ME, Osman D.

Breast Cancer (Auckl). 2015 Sep 6;9:73-9. doi: 10.4137/BCBCR.S29268. eCollection 2015. Review.

15.

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.

Bayraktar S, Royce M, Stork-Sloots L, de Snoo F, Glück S.

Med Oncol. 2014 Oct;31(10):163. doi: 10.1007/s12032-014-0163-9. Epub 2014 Sep 4.

PMID:
25186065
16.

HER2-targeted therapy for early-stage breast cancer: a comprehensive review.

Brown-Glaberman U, Dayao Z, Royce M.

Oncology (Williston Park). 2014 Apr;28(4):281-9. Review.

17.

Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides.

Lu J, Hathaway HJ, Royce ME, Prossnitz ER, Miao Y.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):725-30. doi: 10.1016/j.bmcl.2013.12.120. Epub 2014 Jan 6.

18.

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK; American College of Surgeons Oncology Group investigators.

Lancet Oncol. 2013 Dec;14(13):1317-25. doi: 10.1016/S1470-2045(13)70502-3. Epub 2013 Nov 13.

19.

Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides.

Guo H, Hathaway H, Royce ME, Prossnitz ER, Miao Y.

Bioorg Med Chem Lett. 2013 Oct 15;23(20):5484-7. doi: 10.1016/j.bmcl.2013.08.075. Epub 2013 Aug 23.

20.

Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.

Arias-Pulido H, Chaher N, Gong Y, Qualls C, Vargas J, Royce M.

BMC Cancer. 2012 Jul 19;12:298. doi: 10.1186/1471-2407-12-298.

21.

Quantitative mapping of total choline in healthy human breast using proton echo planar spectroscopic imaging (PEPSI) at 3 Tesla.

Zhao C, Bolan PJ, Royce M, Lakkadi N, Eberhardt S, Sillerud L, Lee SJ, Posse S.

J Magn Reson Imaging. 2012 Nov;36(5):1113-23. doi: 10.1002/jmri.23748. Epub 2012 Jul 10.

22.

The Aboriginal Medical Service Redfern--improving access to primary care for over 40 years.

Marles E, Frame C, Royce M.

Aust Fam Physician. 2012 Jun;41(6):433-6.

23.

Early breast cancer with positive margins: excellent local control with an upfront brachytherapy boost.

Schroeder TM, Liem B, Sampath S, Thompson WR, Longhurst J, Royce M.

Breast Cancer Res Treat. 2012 Jul;134(2):719-25. doi: 10.1007/s10549-012-2087-4. Epub 2012 May 16.

PMID:
22588673
24.

The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.

Candelaria-Quintana D, Dayao ZR, Royce ME.

Breast Cancer Res Treat. 2012 Apr;132(2):355-63. doi: 10.1007/s10549-011-1800-z. Epub 2011 Oct 11. Review.

PMID:
21987034
25.

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.

Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN.

Breast Cancer Res Treat. 2011 Nov;130(1):123-31. doi: 10.1007/s10549-011-1698-5. Epub 2011 Aug 9.

26.

Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides.

Guo H, Lu J, Hathaway H, Royce ME, Prossnitz ER, Miao Y.

Bioconjug Chem. 2011 Aug 17;22(8):1682-9. doi: 10.1021/bc200252j. Epub 2011 Jul 20.

27.

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.

Glück S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, Wu L.

Breast Cancer Res Treat. 2012 Apr;132(3):781-91. doi: 10.1007/s10549-011-1412-7. Epub 2011 Mar 4.

PMID:
21373875
28.

Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.

Chaher N, Arias-Pulido H, Terki N, Qualls C, Bouzid K, Verschraegen C, Wallace AM, Royce M.

Breast Cancer Res Treat. 2012 Jan;131(2):437-44. doi: 10.1007/s10549-011-1422-5. Epub 2011 Mar 1.

29.

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.

Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB.

J Clin Oncol. 2011 Mar 10;29(8):1014-21. doi: 10.1200/JCO.2009.27.6543. Epub 2011 Jan 10.

30.

Method of detection and breast cancer survival disparities in Hispanic women.

Hill DA, Nibbe A, Royce ME, Wallace AM, Kang H, Wiggins CL, Rosenberg RD.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2453-60. doi: 10.1158/1055-9965.EPI-10-0164. Epub 2010 Sep 14.

31.

A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.

Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA.

J Clin Oncol. 2010 Oct 10;28(29):4513-20. doi: 10.1200/JCO.2009.26.9696. Epub 2010 Sep 13.

32.

Polymorphisms in cytokine genes and serum cytokine levels among New Mexican women with and without breast cancer.

Erdei E, Kang H, Meisner A, White K, Pickett G, Baca C, Royce M, Berwick M.

Cytokine. 2010 Jul;51(1):18-24. doi: 10.1016/j.cyto.2010.03.014. Epub 2010 Apr 24.

33.

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.

Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ.

Clin Cancer Res. 2010 Mar 15;16(6):1904-14. doi: 10.1158/1078-0432.CCR-09-2282. Epub 2010 Mar 9.

34.

Bone scan demonstration of osteoblastic tumor of the breast.

Wallace AM, Rosenberg RD, Royce ME.

Surgery. 2011 Jul;150(1):135-6. doi: 10.1016/j.surg.2009.10.062. Epub 2010 Jan 4. No abstract available.

PMID:
20045544
35.

Prognostic value of nodal ratios in node-positive breast cancer: a compiled update.

Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, Promish D, Ueno NT, Tai P, Nieto Y, Joseph S, Janni W, Vicini F, Royce M, Storme G, Wallace AM, Vlastos G, Bouchardy C, Hortobagyi GN.

Future Oncol. 2009 Dec;5(10):1585-603. doi: 10.2217/fon.09.129. Review.

PMID:
20001797
36.

GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.

Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M.

Breast Cancer Res Treat. 2010 Aug;123(1):51-8. doi: 10.1007/s10549-009-0631-7. Epub 2009 Nov 10.

37.

A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

Fekrazad HM, Verschraegen CF, Royce M, Smith HO, Chyi Lee F, Rabinowitz I.

Am J Clin Oncol. 2010 Aug;33(4):393-7. doi: 10.1097/COC.0b013e3181b2043f.

PMID:
19884803
38.

Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.

Wray J, Williamson EA, Royce M, Shaheen M, Beck BD, Lee SH, Nickoloff JA, Hromas R.

PLoS One. 2009;4(4):e5323. doi: 10.1371/journal.pone.0005323. Epub 2009 Apr 24.

39.

The effect of adjuvant radiotherapy on mortality differs according to primary tumor location in women with node-positive breast cancer.

Vinh-Hung V, Truong PT, Janni W, Nguyen NP, Vlastos G, Cserni G, Royce ME, Woodward WA, Promish D, Tai P, Soete G, Balmer-Majno S, Cutuli B, Storme G, Bouchardy C.

Strahlenther Onkol. 2009 Mar;185(3):161-8; discussion 169. doi: 10.1007/s00066-009-1921-z. Epub 2009 Mar 28.

PMID:
19330292
40.

XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer.

Glück S, McKenna EF Jr, Royce M.

Int J Med Sci. 2008;5(6):341-6. Epub 2008 Nov 4.

41.

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F, Smith H, Eberhardt S, Maestas A, Lu H, Verschraegen C.

Invest New Drugs. 2009 Apr;27(2):153-8. doi: 10.1007/s10637-008-9172-x. Epub 2008 Sep 5.

PMID:
18773144
42.

Breast disease: benign and malignant.

Meisner AL, Fekrazad MH, Royce ME.

Med Clin North Am. 2008 Sep;92(5):1115-41, x. doi: 10.1016/j.mcna.2008.04.003. Review.

PMID:
18721655
43.

Idiopathic granulomatous lobular mastitis masquerading as a breast abscess and breast carcinoma.

Marriott DA, Russell J, Grebosky J, Wallace AM, Joste N, Royce ME.

Am J Clin Oncol. 2007 Oct;30(5):564-5. No abstract available.

PMID:
17921721
44.

Marinol-induced gynecomastia: a case report.

Allen RC, Wallace AM, Royce M.

Am J Med. 2007 Oct;120(10):e1. No abstract available.

PMID:
17904434
45.

Disparities in cancer care among racial and ethnic minorities.

Kolb B, Wallace AM, Hill D, Royce M.

Oncology (Williston Park). 2006 Sep;20(10):1256-61; discussion 1261, 1265, 1268-70. Review.

46.

Prognostic value of nodal ratios in node-positive breast cancer.

Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y.

J Clin Oncol. 2006 Jun 20;24(18):2910-6. Review.

PMID:
16782931
47.

Effects of radiotherapy and surgery for early breast cancer.

Promish D, Tai P, Royce M, Vlastos G, Storme G.

Lancet. 2006 May 20;367(9523):1652; author reply 1654-5. No abstract available.

PMID:
16714178
48.

Modeling the effect of age in T1-2 breast cancer using the SEER database.

Tai P, Cserni G, Van De Steene J, Vlastos G, Voordeckers M, Royce M, Lee SJ, Vinh-Hung V, Storme G.

BMC Cancer. 2005 Oct 8;5:130.

49.
50.

Modeling the effect of tumor size in early breast cancer.

Verschraegen C, Vinh-Hung V, Cserni G, Gordon R, Royce ME, Vlastos G, Tai P, Storme G.

Ann Surg. 2005 Feb;241(2):309-18.

Supplemental Content

Support Center